

## University of Groningen

### Erratum to

Johnson, Martin; Kozielska, Magdalena; Pilla Reddy, Venkatesh; Vermeulen, An; Barton, Hugh A; Grimwood, Sarah; de Greef, Rik; Groothuis, Geny M M; Danhof, Meindert; Proost, Johannes H

*Published in:*  
Pharmaceutical Research

*DOI:*  
[10.1007/s11095-016-1888-2](https://doi.org/10.1007/s11095-016-1888-2)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2016

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Johnson, M., Kozielska, M., Pilla Reddy, V., Vermeulen, A., Barton, H. A., Grimwood, S., de Greef, R., Groothuis, G. M. M., Danhof, M., & Proost, J. H. (2016). Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D<sub>2</sub> Receptor Occupancy. *Pharmaceutical Research*, 33(5), 1305-1306. <https://doi.org/10.1007/s11095-016-1888-2>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

## Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D<sub>2</sub> Receptor Occupancy

Martin Johnson<sup>1,6</sup> • Magdalena Kozielska<sup>1,7</sup> • Venkatesh Pilla Reddy<sup>1,6</sup> • An Vermeulen<sup>2</sup> • Hugh A. Barton<sup>3</sup> • Sarah Grimwood<sup>3</sup> • Rik de Greef<sup>4</sup> • Geny M. M. Groothuis<sup>1</sup> • Meindert Danhof<sup>5</sup> • Johannes H. Proost<sup>1</sup>

Published online: 10 March 2016

© The Author(s) 2016. This article is published with open access at SpringerLink.com

### Erratum to: Pharm Res

DOI 10.1007/s11095-015-1846-4

There occurred two errors in the above manuscript (Pharm Res. 2015 Dec 30 [Epub ahead of print]). The correct information is as follows:

- 1) The differential equations in Appendix 2 should read:

$$\begin{aligned}d(A_{bv})/dt &= (CL_{bv}/V_{plasma}) * A_{plasma} - (CL_{bv}/V_{bv}) * A_{bv} - (CL_{bv}/V_{bv}) * fu_{plasma} * A_{bv} \\&+ (CL_{bv}/V_{bv}) * fu_{brain} * A_{bev} + (CL_{eff}/V_{bev}) * fu_{brain} * A_{bev} \\d(A_{bev})/dt &= (CL_{bv}/V_{bv}) * fu_{plasma} * A_{bv} - (CL_{bv}/V_{bev}) * fu_{brain} * A_{bev} - (CL_{eff}/V_{bev}) * fu_{brain} * A_{bev} \\&- (CL_{st}/V_{bev}) * fu_{brain} * A_{bev} + (CL_{st}/V_{stf}) * fu_{brain} * A_{stf} \\d(A_{stf})/dt &= (CL_{st}/V_{bev}) * fu_{brain} * A_{bev} - (CL_{st}/V_{stf}) * fu_{brain} * A_{stf} - kon * fu_{brain} * A_{stf} * (B_{max} - CB) \\&+ koff * A_{stb} \\d(A_{stb})/dt &= kon * fu_{brain} * A_{stf} * (B_{max} - CB) - koff * A_{stb}\end{aligned}$$

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11095-015-1846-4>.

---

✉ Johannes H. Proost  
[j.h.proost@rug.nl](mailto:j.h.proost@rug.nl)

- <sup>1</sup> Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
- <sup>2</sup> Clinical Pharmacology & Pharmacometrics, Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
- <sup>3</sup> Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut, USA
- <sup>4</sup> Quantitative Solutions, Pivot Park, Molenweg 79, 5349 AC Oss, The Netherlands
- <sup>5</sup> Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden, The Netherlands
- <sup>6</sup> Present address: AstraZeneca, Cambridge, UK
- <sup>7</sup> Present address: Institute of Engineering, Hanze University of Applied Sciences, Assen, The Netherlands

2) Table III should read:

**Table III** *In vitro*, *in vivo* and *ex vivo* values estimates used in the human D<sub>2</sub>RO predictive model.

	Clozapine	Haloperidol	Olanzapine	Paliperidone	Quetiapine	Risperidone
Fraction unbound in brain	0.011 <sup>a</sup>	0.023 <sup>b</sup>	0.034 <sup>a</sup>	0.0755 <sup>c</sup>	0.025 <sup>a</sup>	0.0699 <sup>c</sup>
Fraction unbound in plasma	0.0300 <sup>d</sup>	0.0800 <sup>e</sup>	0.0700 <sup>m</sup>	0.226 <sup>f</sup>	0.170 <sup>e</sup>	0.100 <sup>f</sup>
Approach A: Human D <sub>2</sub> RO predictions based on <i>in vitro</i> information						
Papp × 10 <sup>-6</sup> (cm/s)	28.3 <sup>a</sup>	28.6 <sup>a</sup>	15.7 <sup>a</sup>	16.8 <sup>g</sup>	33.0 <sup>a</sup>	19.8 <sup>g</sup>
CL <sub>be<sub>v</sub></sub> (L/h) derived from Papp	20.4	20.6	11.3	7.80	23.8	12.96
Efflux ratio	—	—	—	2.10 <sup>g</sup>	—	1.20 <sup>g</sup>
CL <sub>eff</sub> (L/h) based on ER	—	—	—	8.58	—	2.59
<i>In vitro</i> K <sub>i</sub> (nM)	82.0 <sup>h</sup>	0.700 <sup>h</sup>	5.10 <sup>i</sup>	2.075 <sup>e</sup>	155 <sup>h</sup>	2.175 <sup>e</sup>
k <sub>off</sub> (h <sup>-1</sup> )	83.16 <sup>h</sup>	1.02 <sup>h</sup>	2.34 <sup>h</sup>	1.56 <sup>j,n</sup>	180.78 <sup>h</sup>	1.56 <sup>j</sup>
Approach B: Human D <sub>2</sub> RO predictions based on <i>in vivo</i> information						
Papp <sub>calc</sub> × 10 <sup>-6</sup> (cm/s)	—	—	100	493 <sup>n</sup>	—	493
CL <sub>be<sub>v</sub></sub> (L/h) based on Papp <sub>calc</sub>	—	—	72.2	355 <sup>n</sup>	—	355
CL <sub>eff</sub> (L/h) scaled from rat	—	—	NA	11594	—	2486
k <sub>off</sub> (h <sup>-1</sup> )	—	—	3.04 <sup>k</sup>	0.671 <sup>l,n</sup>	—	0.671 <sup>l</sup>
Approach C: Human D <sub>2</sub> RO predictions integrating <i>in vitro</i> and <i>in vivo</i> information						
Corrected <i>In vivo</i> K <sub>d</sub> (nM)	—	—	4.38	0.352	—	0.395

NA Not applicable

<sup>a</sup> Reference (32); <sup>b</sup> Reference (33); <sup>c</sup> Reference (34); <sup>d</sup> Reference (35); <sup>e</sup> In-house values; <sup>f</sup> Reference (36); <sup>g</sup> Reference (37);

<sup>h</sup> Reference (38); <sup>i</sup> Reference (39); <sup>j</sup> Reference (5); <sup>k</sup> Reference (7); <sup>l</sup> Reference (8); <sup>m</sup> Reference (40); <sup>n</sup> Assumed to be equal to risperidone